Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

1

Ulutas Med J. 2015; 1(4): 104-110


Venous Thromboembolism Prophylaxis in Obese Medical Patients: a Retrospective Cohort Study

Duane Bates, Lauren Breese, Cindy brocklebank, kelly zarnke, Peter Jamieson, Elizabeth Mackay.

Abstract
Background: The incidence of obesity has increased 3 fold in Canada between 1985 and 2011. Obese patients are 2-3 times more likely to develop venous thromboembolism (VTE), and over 60% of VTE occurs in hospital. There is very little literature on VTE prophylaxis in the obese medical patient.
Objective(s): Our primary objective was to identify the incidence of objectively documented symptomatic VTE during hospitalization or up to ninety days post discharge. Our secondary objectives were to describe the prescribing patterns of VTE prophylaxis received in hospitalized obese medical patients (body mass index [BMI] ≥ 30 kg/m2) as well as risk factors for VTE in obese patients.
Methods: A retrospective design was used look at obese patients admitted to a general medicine service at three tertiary care academic teaching hospitals in Calgary, AB, Canada from January 1, 2012 to December 31, 2012. VTE was identified based on clinical diagnosis and incidence was calculated.
Results: There were 443 patients included in the analysis. The average age and BMI were 58.5 years and 41 kg/m2 respectively, and 70.2% were males. The median length of stay in hospital was 7 days (IQR 4-13). A total of 122 patients (27.5%) of patients did not receive thromboprophylaxis during their hospitalization. Unfractionated heparin (UFH) was the most common agent prescribed (37.9%), and only seven patients received high-dose thromboprophylaxis. The median duration of prophylaxis was 6.5 days (IQR 4-12). Seven patients (1.6%) developed VTE (5 pulmonary embolism and 2 DVT) during the study period, and six of these patients received thromboprophylaxis. In terms of risk for VTE, the median Padua Prediction Score for the study group was 2 (IQR 1-3).
Conclusion: There is very little literature on VTE prophylaxis and incidence of VTE in the obese medical patient. Given the low risk for and incidence of VTE in this study, particularly in the context of 27.5% of the study population not receiving thromboprophylaxis, there is a need for further research to evaluate the efficacy and safety of high dose thromboprophylaxis in the obese medical patient.

Key words: Venous thrombosis, thromboprophylaxis, medical patient, obesity



Share this Article


Advertisement
Journal of Molecular Pathophysiology

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.
Scopemed Buttons